CTOs on the Move

The DNA Repair Company

www.dnar.com

 
The DNA Repair Company is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dnar.com
  • 1 Kendall Sq Bldg 300
    Cambridge, MA USA 02139
  • Phone: 617.517.3210

Executives

Name Title Contact Details

Similar Companies

Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.

IVFCRYO

Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.

Thallion Pharmaceuticals

Thallion Pharmaceuticals is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-Path Holdings

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.

Zucara Therapeutics

Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.